FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127971692> ?p ?o ?g. }

• W2127971692 endingPage "2619" @default.
• W2127971692 startingPage "2613" @default.
• W2127971692 abstract "ABSTRACT Multidrug-resistant tuberculosis (MDR-TB) threatens global TB control. The lengthy treatment includes one of the injectable drugs kanamycin, amikacin, and capreomycin, usually for the first 6 months. These drugs have potentially serious toxicities, and when given as intramuscular injections, dosing can be painful. Advances in particulate drug delivery have led to the formulation of capreomycin as the first antituberculosis drug available as a microparticle dry powder for inhalation and clinical study. Delivery by aerosol may result in successful treatment with lower doses. Here we report a phase I, single-dose, dose-escalating study aimed at demonstrating safety and tolerability in healthy subjects and measuring pharmacokinetic (PK) parameters. Twenty healthy adults ( n = 5 per group) were recruited to self-administer a single dose of inhaled dry powder capreomycin (25-mg, 75-mg, 150-mg, or 300-mg nominal dose) using a simple, handheld delivery device. Inhalations were well tolerated by all subjects. The most common adverse event was mild to moderate transient cough, in five subjects. There were no changes in lung function, audiometry, or laboratory parameters. Capreomycin was rapidly absorbed after inhalation. Systemic concentrations were detected in each dose group within 20 min. Peak and mean plasma concentrations of capreomycin were dose proportional. Serum concentrations exceeded 2 μg/ml (MIC for Mycobacterium tuberculosis ) following the highest dose; the half-life ( t 1/2 ) was 4.8 ± 1.0 h. A novel inhaled microparticle dry powder formulation of capreomycin was well tolerated. A single 300-mg dose rapidly achieved serum drug concentrations above the MIC for Mycobacterium tuberculosis , suggesting the potential of inhaled therapy as part of an MDR-TB treatment regimen." @default.
• W2127971692 created "2016-06-24" @default.
• W2127971692 creator A5015413436 @default.
• W2127971692 creator A5026332726 @default.
• W2127971692 creator A5054501041 @default.
• W2127971692 creator A5064304201 @default.
• W2127971692 creator A5071846305 @default.
• W2127971692 creator A5090582190 @default.
• W2127971692 date "2013-06-01" @default.
• W2127971692 modified "2023-10-06" @default.
• W2127971692 title "Phase I, Single-Dose, Dose-Escalating Study of Inhaled Dry Powder Capreomycin: a New Approach to Therapy of Drug-Resistant Tuberculosis" @default.
• W2127971692 cites W1909237381 @default.
• W2127971692 cites W1922421553 @default.
• W2127971692 cites W1969988673 @default.
• W2127971692 cites W1979618878 @default.
• W2127971692 cites W1996794787 @default.
• W2127971692 cites W2004143013 @default.
• W2127971692 cites W2021043336 @default.
• W2127971692 cites W2043598462 @default.
• W2127971692 cites W2043791602 @default.
• W2127971692 cites W2048390434 @default.
• W2127971692 cites W2056858263 @default.
• W2127971692 cites W2059056863 @default.
• W2127971692 cites W2059934442 @default.
• W2127971692 cites W2090542083 @default.
• W2127971692 cites W2094532887 @default.
• W2127971692 cites W2101883647 @default.
• W2127971692 cites W2103716690 @default.
• W2127971692 cites W2126660142 @default.
• W2127971692 cites W2132491970 @default.
• W2127971692 cites W2132709463 @default.
• W2127971692 cites W2134391509 @default.
• W2127971692 cites W2140828933 @default.
• W2127971692 cites W3184554648 @default.
• W2127971692 cites W4212818152 @default.
• W2127971692 doi "https://doi.org/10.1128/aac.02346-12" @default.
• W2127971692 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3716148" @default.
• W2127971692 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23529740" @default.
• W2127971692 hasPublicationYear "2013" @default.
• W2127971692 type Work @default.
• W2127971692 sameAs 2127971692 @default.
• W2127971692 citedByCount "109" @default.
• W2127971692 countsByYear W21279716922013 @default.
• W2127971692 countsByYear W21279716922014 @default.
• W2127971692 countsByYear W21279716922015 @default.
• W2127971692 countsByYear W21279716922016 @default.
• W2127971692 countsByYear W21279716922017 @default.
• W2127971692 countsByYear W21279716922018 @default.
• W2127971692 countsByYear W21279716922019 @default.
• W2127971692 countsByYear W21279716922020 @default.
• W2127971692 countsByYear W21279716922021 @default.
• W2127971692 countsByYear W21279716922022 @default.
• W2127971692 countsByYear W21279716922023 @default.
• W2127971692 crossrefType "journal-article" @default.
• W2127971692 hasAuthorship W2127971692A5015413436 @default.
• W2127971692 hasAuthorship W2127971692A5026332726 @default.
• W2127971692 hasAuthorship W2127971692A5054501041 @default.
• W2127971692 hasAuthorship W2127971692A5064304201 @default.
• W2127971692 hasAuthorship W2127971692A5071846305 @default.
• W2127971692 hasAuthorship W2127971692A5090582190 @default.
• W2127971692 hasBestOaLocation W21279716921 @default.
• W2127971692 hasConcept C112705442 @default.
• W2127971692 hasConcept C126322002 @default.
• W2127971692 hasConcept C142724271 @default.
• W2127971692 hasConcept C197934379 @default.
• W2127971692 hasConcept C2776042228 @default.
• W2127971692 hasConcept C2776228421 @default.
• W2127971692 hasConcept C2776954882 @default.
• W2127971692 hasConcept C2776991065 @default.
• W2127971692 hasConcept C2777419714 @default.
• W2127971692 hasConcept C2777975735 @default.
• W2127971692 hasConcept C2778375690 @default.
• W2127971692 hasConcept C2779806340 @default.
• W2127971692 hasConcept C2780261241 @default.
• W2127971692 hasConcept C2781019175 @default.
• W2127971692 hasConcept C2781069245 @default.
• W2127971692 hasConcept C42219234 @default.
• W2127971692 hasConcept C71924100 @default.
• W2127971692 hasConcept C98274493 @default.
• W2127971692 hasConceptScore W2127971692C112705442 @default.
• W2127971692 hasConceptScore W2127971692C126322002 @default.
• W2127971692 hasConceptScore W2127971692C142724271 @default.
• W2127971692 hasConceptScore W2127971692C197934379 @default.
• W2127971692 hasConceptScore W2127971692C2776042228 @default.
• W2127971692 hasConceptScore W2127971692C2776228421 @default.
• W2127971692 hasConceptScore W2127971692C2776954882 @default.
• W2127971692 hasConceptScore W2127971692C2776991065 @default.
• W2127971692 hasConceptScore W2127971692C2777419714 @default.
• W2127971692 hasConceptScore W2127971692C2777975735 @default.
• W2127971692 hasConceptScore W2127971692C2778375690 @default.
• W2127971692 hasConceptScore W2127971692C2779806340 @default.
• W2127971692 hasConceptScore W2127971692C2780261241 @default.
• W2127971692 hasConceptScore W2127971692C2781019175 @default.
• W2127971692 hasConceptScore W2127971692C2781069245 @default.
• W2127971692 hasConceptScore W2127971692C42219234 @default.
• W2127971692 hasConceptScore W2127971692C71924100 @default.
• W2127971692 hasConceptScore W2127971692C98274493 @default.
• W2127971692 hasIssue "6" @default.

• next